Femoral Nerve Block Bupivacaine — Competitive Intelligence Brief

Femoral Nerve Block Bupivacaine (Femoral Nerve Block Bupivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia / Pain Management.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

Femoral Nerve Block Bupivacaine (Femoral Nerve Block Bupivacaine) — The New England Baptist Hospital. Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the femoral nerve distribution.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Femoral Nerve Block Bupivacaine TARGET	Femoral Nerve Block Bupivacaine	The New England Baptist Hospital	phase 3	Local anesthetic	Voltage-gated sodium channels
dexmedetomidine-esketamine-ropivacaine combination 1	dexmedetomidine-esketamine-ropivacaine combination 1	Peking University First Hospital	marketed	Combination anesthetic/analgesic	Alpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels
Trileptal®	Trileptal®	Teva Pharmaceuticals USA	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Benzocaine oral gel 20%	Benzocaine oral gel 20%	Dina Youssef Attia	marketed	Local anesthetic	Voltage-gated sodium channels
Surgeon-Initiated Local Anesthetic	Surgeon-Initiated Local Anesthetic	University of Wisconsin, Madison	marketed	Local anesthetic	Voltage-gated sodium channels
Intracervical lidocaine	Intracervical lidocaine	Bayero University Kano, Nigeria	marketed	Local anesthetic	Voltage-gated sodium channels
MgSO4 plus Ropivacaine	MgSO4 plus Ropivacaine	Hospital Universiti Sains Malaysia	marketed	Local anesthetic adjuvant combination	Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class